

Date: 8<sup>th</sup> December, 2025

To,  
 Corporate Relations Department  
**National Stock Exchange of India Limited**  
 Exchange Plaza, C-1, Block G,  
 Bandra Kurla Complex,  
 Bandra (E), Mumbai – 400 051  
**Company Code: ACCPL**

Dear Sir/Madam,

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Schedule of Investor/Analyst Meet**

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time), we wish to inform that the management of the Company will be participating in-person with the following Analyst/ Investor at Mumbai:

<b>Date and Day</b>	<b>Type of Meeting</b>	<b>Company Name</b>
11/12/2025 Thursday	One on one meeting	Arjav Partners
	Group Meeting	Saffire Capital
		HNI
		Eqilion
	Group Meeting	Perpetuity Ventures
		IMAP India
		Vision 8 Investments
		PM Consultancy
	One on one meeting	Nuvama Wealth
	One on one meeting	HNI
One on one meeting	P4 Capital	

The above schedule is subject to change which may happen due to exigencies on part of the Company/ Analyst/ Investor.

The Discussions with the investor/Analyst will be based on generally available information and will not involve any Unpublished Price Sensitive Information as per Accretion Pharmaceuticals Limited Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

Pursuant to regulation 46(2) of the Listing Regulations, aforesaid information shall be disclosed on the website of the company viz [www.accretionpharma.com](http://www.accretionpharma.com).

Thanking You,  
 Yours faithfully,  
**For Accretion Pharmaceuticals Limited**

**Roshni Shah**  
**Company Secretary and Compliance Officer**